The linked successes of dialysis and transplantation pose dilemmas for nephrologists struggling to meet the clinical need and for health care planners wondering where to find the resources required. The low rate of acceptance of new patients in the UK compares unfavourably with the service given in other countries. Successful rationing is achieved by a sparse distribution of centres and of specialists and operates through a low rate ofreferral ofpatients to nephrologists. Political initiative is beginning to emerge to redress the underprovision offacilities by setting realistic targets before regional health authorities.
INTRODUCTION: DILEMMAS POSED BY SUCCESS
It is the success of dialysis and kidney transplantation during the past 25 years which now poses dilemmas for nephrologists and nations. Renal replacement therapy (RRT) prolongs life for patients who would otherwise die of end-stage renal failure (ESRF). This life is of a reasonable quality and patients have an expectation that RRT will be offered to them if they need it.
The modern treatment of ESRF consists of complementary dialysis and transplantation. Most renal units have available both haemodialysis and peritoneal dialysis. Haemodialysis is carried out both in the hospital unit and by patients in their own homes. Peritoneal dialysis when used for long-term therapy is usually administered as continuous ambulatory peritoneal dialysis (CAPD). Individual patients may experience all these methods of therapy at various times in their careers on RRT. The treatments are thus termed 'integrated'. Reasons for choice of one therapy at a particular time include patient preference as well as medical and domestic considerations. Inevitably, economic factors enter into such deliberations and it is seldom possible to take these decisions for an individual without weighing their effect on the group of patients in a programme. This paper presents data from the patient registry organised by the European Dialysis and Transplant Association-European Renal Association (EDTA-ERA) to illustrate the differences in provision of RRT in various European countries.' Mechanisms which ration high cost medical care in the United Kingdom have been investigated.2 Ethical dilemmas for governments which provide health care and for doctors in this case nephrologists who dispense it are becoming ever more painful.
THE COST OF DIALYSIS AND TRANSPLANTATION
RRT is expensive. The price is excessive for poor nations and not without embarrassment for the wealthier. It is a popular misconception that the cost of treatment is the price of a kidney machine. The capital cost of a machine which manufactures dialysis fluid and monitors the dialysis procedure is around £5,000 to £6,000. The revenue implications in terms of consumables -disposable dialysers, blood lines, dressings and drugs -amount to a further £2,000 to £3,000 per annum. In addition there are the overheads of the renal unit and its staff. Overall costs of the different methods of dialysis and of transplantation in its first and subsequent years are given in Table 1 .3 Successful transplantation is obviously the 'best buy'. From this the economic importance of cadaver procurement is evident. However, nearly all patients experience a short or long period on dialysis while waiting for a suitable graft, and dialysis should also be provided for patients whose grafts have failed. A graft carries greater risks for certain patients but risks are diminishing as results improve and its lower cost will encourage doctors to offer transplantation to a wider spectrum of patients with ESRF. 
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Cost of dialysis and transplantation S65 Table 11 shows the number of centres providing treatment and the cumulative stock of patients in each country, each figure being given per million of population to facilitate comparisons. The number of centres is a constraint on patient numbers and the low number of patients in the United Kingdom, only 153 patients per million population (pmp), is obviously related to the restricted number of centres, 1.1 pmp. Average work load per UK centre is thus much greater than in the average European centre indicating that British centres tend to be larger and probably more cost-effective. The stock of patients describes the current work load and the staff and facilities are related to this. The opportunity for a new patient to obtain treatment is determined by the rate of acceptance of new cases and Table III shows the rates for patients aged under and over 65 in different countries. The low acceptance rate in the UK particularly disadvantages patients aged more than 65. Not only do the constraints operating in the UK limit patient numbers, they also have a marked effect on the distribution of patients between different treatment modalities (Fig 1) . Because of the limitation of hospital stations in the UK, patients who can only be treated by hospital haemodialysis (Fig 2) are accepted with reluctance because they might block hospital facilities which are the corridor to home haemodialysis, CAPD, and transplantation. It may be thought commendable that individual doctors can shoulder such a responsibility. That they can do so at all probably owes much to the social structure of our country and the traditional paternalism of our learned professions. In the face of such a system, which patients are likely to get through to the renal unit? The young and beautiful, certainly. The articulate and aggressive, possibly. Those whose families, parents, children and friends will take up their cause. The request for a second opinion is a rarely exercised privilege under the NHS. Media publicity suggests that it should be invoked more often. 7 In the meantime, a rough and ready system of triage is at work maintaining a delicate equilibrium between clinical need and available facilities. Health for Wales who has announced his intention to treat 50 patients pmp. Subsidiary renal units are being opened in Wales to accomplish this and the experiment in the Principality will be watched with great interest by the rest of the UK. Northern Ireland has no plans, so far as I know, to augment its single renal unit which has made such a famous contribution over the last 25 years. Perhaps limited facilities could be used more intensively, by the institution of an overnight programme,9 and perhaps the addition of CAPD to the treatment options will ease the pressures under which Dr McGeown and her staff are serving the population of Ulster. Good luck for the years ahead!
